Canadian Association of Radiation Oncology (CARO)

Canadian Association of Radiation Oncology (CARO)
Abbott Oncology

Abbott Oncology

May 29, 2012 08:30 ET

$195,000 Awarded for Nine Innovative Prostate Cancer Research Programs-2012 CARO/Abbott Oncology ACURA Uro-Oncologic Radiation Awards

OTTAWA, ONTARIO--(Marketwire - May 29, 2012) - Nine leading Canadian radiation oncologists are exploring next generation enhancements to prostate cancer treatment with support from Abbott Oncology's ACURA Uro-Oncologic Radiation Awards. A selection committee of members of the Canadian Association of Radiation Oncology selected the 2012 recipients from among a field of 21 applicants.

Dr. Fabio Cury of McGill University and advisory group chair, explains, "The ACURA Award program provides a unique and highly valued source of seed funding for basic science, translational, clinical and population-based prostate cancer research. A total of 102 Canadian projects have been funded in the past eleven years, totaling $2,295,000."

2012 Award Recipients:

$11,750 to Dr. Winkle Kwan and Co-Investigator, Dr. Tsz Kin Lee of BC Cancer Agency's Fraser Valley Centre for: Development and Validation of EPIC in Chinese and Punjabi.

$12,250 to Dr. Mira Keyes of BC Cancer Agency's Vancouver Cancer Centre for: British Columbia Registration Trial: Radical Prostatectomy vs. Dose Escalation with LDR Brachytherapy for High Tier and High Risk Prostate Cancer.

$27,000 to Dr. George Rodrigues of London Health Sciences Centre for: The Prostate Cancer Risk Stratification (ProCaRS) Project: Predicting Patient Outcomes using Neural Networks and Clinical Nomograms.

$23,500 to Dr. Hans Chung of Odette Cancer Centre, Sunnybrook Health Sciences Centre for: Pilot Study of Focal Salvage HDR Prostate Brachytherapy.

$27,000 to Dr. Stanley Liu of Odette Cancer Centre, Sunnybrook Health Sciences Centre for: Targeting the Angiopoietin-1-Tie2 axis to Improve Therapeutic Ratio of Prostate Radiotherapy.

$20,000 to Dr. Rob Dinniwell, and Co-Investigator, Dr. Wilfred Levin of Princess Margaret Hospital, University Health Network, Toronto for: Double-Blind, Placebo-Controlled, Two Way Cross Over Study of Topical Phenylephrine for Passive Fecal Incontinence Following Radiotherapy in Men with Prostate Cancer.

$27,000 to Dr. Theodoros Tsakiridis of Juravinski Cancer Centre, Radiation Oncology for: Circulating Pro-Inflammatory Cytokines (cPIC) as biomarkers of Gastrointestinal and Genitourinary Toxicity in Patients Undergoing Pelvic Radiotherapy for Prostate Cancer.

$26,750 to Dr. Eric Vigneault of CHUQ l'Hotel-Dieu de Quebec for: Randomized Phase Two Feasibility Trial of High Dose Rate Brachytherapy plus External Beam Radiotherapy in Patients with Intermediate-Risk Prostate Cancer.

$20,000 to Dr. Daniel Bernad of McGill University for: Study on the Effects of Androgen Deprivation Therapy on Memory Processing and Neurogenisis in Patients with Non-Metastatic Prostate Cancer.

Each Award Recipient's BioSketch, Photograph, and Full Statement of Purpose in easy-to-understand language is located on the CARO-ACRO web site at the following link:

To interview any of the Award Recipients: Judy McLarty, 604.740.5839 or

About the Canadian Association of Radiation Oncology

Canadian Association of Radiation Oncology (CARO) - Association canadienne de radio-oncologie (ACRO) is a not-for-profit association with the mandate to represent and support its membership nationally and internationally, through the promotion of high standards of patient care in the practice of radiation oncology, support of excellence in professional standards, and promotion of radiation oncology research and education.

CARO is a partner with other disciplines in seeking to improve outcomes for cancer patients, and provides a consultative authority to oncology related agencies, academic institutions, and to the public in all matters pertaining to radiotherapy and oncology in Canada. For further information:

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott has been operating in Canada since 1931 and its Canadian operations are headquartered in Montreal, Quebec. Abbott Canada employs more than 2,000 people. Abbott's news releases and other information are available on the company's web sites at and

Contact Information